A confirmatory dose-ranging study of riluzole in ALS

Neurology

Volumn 47, Issue 6 SUPPL. 4, 1996, Pages

  Lacomblez, L ^a   Bensimon, G ^a   Leigh, P N ^d   Guillet, P ^b,c   Powe, L ^b,c   Durrleman, S ^b,c   Delumeau, J C ^b,c   Meininger, V ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SANOFI   (France)

^c Rhone Poulence Rorer   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DEXTROMETHORPHAN; PLACEBO; RILUZOLE; SELEGILINE; THREONINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYOTROPHIC LATERAL SCLEROSIS; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; TABLET; TRACHEOSTOMY; TREATMENT OUTCOME; VERTIGO;

EID: 0029731655     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.47.6_suppl_4.242s     Document Type: Article

References (22)

1. Smith RA, ed. Handbook of amyotrophic lateral sclerosis. New York: Marcel Dekker, 1992.
2. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-634.
3. Shaw PJ. Excitotoxicity and motor neuron disease: a review of the evidence. J Neurol Sci 1994;124(Suppl):1-13.
4. Rothstein JD. Excitatory mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995;68:7-20.
5. Pratt J, Rataud J, Bardot F, et al. Neuroprotective actions of riluzole in rodent models of global and focal ischaemia (ENG). Neurosci Lett 1992;140:225-230.
6. Malgouris C, Daniel M, Doble A. Neuroprotective effects of riluzole on N-methyl-D-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices. Neurosci Lett 1994;177: 95-99.
7. Couratier P, Sindou P, Esclaire F, Louvel E, Hugon J. Neuroprotective effects of riluzole in ALS CSF toxicity. Neuroreport 1994;5:1012-1014.
8. 3H] aspartate release from cultured cerebellar granule cells. Neurosci Lett 1992;140:251-254.
9. Debono M-W, Le Guern J, Canton T, Doble A, Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993;235:283-289.
10. Hubert JP, Delumeau JC, Glowinski J, Promont J, Doble A. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: Evidence for a dual mechanism of action. Br J Pharmacol 1994;113:261-267.
11. Herbert T, Drapeau P, Pradier L, Dunn RJ. Block of the rat brain IIA sodium channel α subunit by the neuroprotective drug riluzole. Mol Pharmacol 1994;45:1055-1060.
12. Bensimon G, Lacomblez L, Meininger V, for the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
13. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
14. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124 Suppl:96-107.
15. Rozier A, Lacomblez L, Chatelier G, Bensimon G, Bouche P, Meininger V. Interrater reliability of a new rating scale for amyotrophic lateral sclerosis [abstract]. J Neurol Sci 1990;98 Suppl:316.
16. Lacomblez L, Bouche P, Bensimon G, Meininger V. A double-blind placebo-controlled trial of high dose gangliosides in amyotrophic lateral sclerosis. Neurology 1989;39:1635-1637.
17. Norris F, Shepherd R, Denys E, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993;118:48-55.
18. Eisen A, Schulzer M, MacNeil M, Pant B, Mak E. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 1993;16:27-32.
19. Tysnes O-B, Vollset SE, Larsen JP, Aarli JA. Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology 1994;13:226-235.
20. Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve 1989;12:833-841.
21. Wu MC, Carroll RJ. Estimation and comparison of changes in the presence of informative right censoring by modeling the censoring process. Biometrics 1988;44:175-188.
22. Guidelines for ATC classification. WHO Collaborating Centre for Drugs Statistics Methodology. Oslo, 1993.